603456.SH
九洲药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 15.71
−5.36%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.2B | 5.5B | 5.2B | 5.5B | 5.4B |
| Cost of Revenue | 3.3B | 3.5B | 3.4B | 3.4B | 3.6B |
| Gross Profit | 1.9B | 2.0B | 1.7B | 2.1B | 1.9B |
| Operating Expenses | |||||
| R&D Expense | 245.5M | 257.0M | 314.9M | 330.8M | 287.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 381.8M | 393.9M | 417.7M | 445.9M | 429.2M |
| Selling & Marketing Expense | 113.5M | 107.7M | 99.9M | 82.0M | 57.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 806.5M | 815.0M | 810.6M | 832.3M | 723.6M |
| Cost and Expenses | 4.1B | 4.3B | 4.2B | 4.3B | 4.3B |
| Operating Income (EBIT) | 833.4M | 924.9M | 732.2M | 1.2B | 1.1B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 828.8M | 919.5M | 730.6M | 1.2B | 1.1B |
| Income Tax Expense | 181.9M | 190.9M | 123.5M | 149.3M | 182.8M |
| Bottom Line | |||||
| Net Income | 652.0M | 730.1M | 606.1M | 1.0B | 921.2M |
| Earnings from Cont. Ops | 646.9M | 728.5M | 607.1M | 1.0B | 921.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 652.0M | 730.1M | 606.1M | 1.0B | 921.2M |
| Per Share | |||||
| Basic EPS | CN¥0.73 | CN¥0.82 | CN¥0.68 | CN¥1.16 | CN¥1.11 |
| Diluted EPS | CN¥0.73 | CN¥0.82 | CN¥0.68 | CN¥1.16 | CN¥1.11 |
| Revenue Per Share | CN¥5.76 | CN¥6.19 | CN¥5.79 | CN¥6.20 | CN¥6.56 |
| Shares | |||||
| Basic Shares Outstanding | 905.7M | 890.3M | 891.3M | 890.7M | 829.9M |
| Diluted Shares Outstanding | 905.7M | 890.3M | 891.3M | 890.7M | 829.9M |
| Profitability Metrics | |||||
| EBITDA | — | 1.3B | 1.1B | 1.6B | 1.5B |
| D&A | — | 417.8M | 405.7M | 377.9M | 344.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026